|
Delayed
NSE India S.E.
14:25:18 15/09/2026 HKT
|
5-day change | 1st Jan Change | ||
| 1,356.30 INR | -0.71% |
|
-2.04% | -10.29% |
| 09-03 | India's Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilar | RE |
| 08-25 | Cipla's Pithampur, India Unit Gets 7 Observations From US FDA | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Generic Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 11.51B | |||||
| 46.06B | |||||
| 38.29B | |||||
| 11.65B | |||||
| 9.17B | |||||
| 7.22B |
- Stock Market
- Stocks
- CIPLA Stock
- Charts Cipla Limited
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
